A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a similar calorie-restricted diet was prescribed to all patients. Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved. Drop-out rate was not significantly different for both groups of patients.
Kutnowski, M., Daubresse, JC., Friedman, H., Kolanowski, J., Krzentowski, G., Scheen, A., & Vangaal, L. (1992). Fluoxetine Therapy in Obese Diabetic and Glucose Intolerant Patients. International Journal of Obesity, 16, S63-S66. https://hdl.handle.net/2078.5/42382 (Original work published 1992)